Tonga Healthcare Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tonga Healthcare Daily.

Press releases published on October 28, 2026

Oct. 28, 2026

Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis

Indeterminate GlobeNewswire

Oct. 28, 2026

Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues

Indeterminate GlobeNewswire

Oct. 28, 2026

Newron Pharmaceuticals to Participate in November Investor Conferences

Indeterminate GlobeNewswire

Oct. 28, 2026

Scipher Medicine Launches PrismTcell™, the Next Molecular Treatment Response Signature, for Abatacept in Rheumatoid Arthritis

Indeterminate GlobeNewswire

Oct. 28, 2026

INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement

Indeterminate GlobeNewswire

Oct. 28, 2026

UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer

Indeterminate GlobeNewswire

Oct. 28, 2026

ORYZON to participate in upcoming events in November

Indeterminate GlobeNewswire

Oct. 28, 2026

Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells

Indeterminate GlobeNewswire

Oct. 28, 2026

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 

Indeterminate GlobeNewswire

Oct. 28, 2026

Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

Indeterminate GlobeNewswire

Oct. 28, 2026

Immutep Receives A$2.16 million French R&D Tax Incentive

Indeterminate GlobeNewswire

Oct. 28, 2026

Blue Lake Biotechnology Secures $5 Million Grant to Support Ongoing Pediatric Phase 1/2a Clinical Trial of Intranasal RSV Vaccine Candidate

Indeterminate GlobeNewswire

Oct. 28, 2026

PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections

Indeterminate GlobeNewswire

Oct. 28, 2026

iTonic Holdings Ltd Regains Compliance with Nasdaq Minimum Bid Price Requirement

Indeterminate GlobeNewswire

Oct. 28, 2026

Global Diabetes Treatment and Innovation Market to Reach $295 Billion by 2031

Indeterminate GlobeNewswire

Oct. 28, 2026

Pyxis Oncology to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire

Oct. 28, 2026

SIGA Secures Contract Valued at Up to $15 Million from Canadian Department of National Defence to Purchase TPOXX®

Indeterminate GlobeNewswire

Oct. 28, 2026

Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set

Indeterminate GlobeNewswire

Oct. 28, 2026

Micron Biomedical Appoints Anand Subramony, Ph.D., as Executive Vice President, Global Product Development and Combination Product Commercialization

Indeterminate GlobeNewswire

Oct. 28, 2026

uniQure to Announce Third Quarter 2026 Financial Results

Indeterminate GlobeNewswire